Shots:
- RadNet has entered into a definitive merger agreement to acquire iCAD in an all-stock transaction, through which iCAD will become a wholly owned subsidiary of RadNet
- As per the deal, iCAD stockholders will receive 0.0677 RadNet shares/ iCAD share, representing transaction value of ~$103M, or ~$3.61/share (~98% premium) on a fully diluted basis; closing expected in Q2 or Q3’25
- Acquisition will integrate iCAD’s AI-driven ProFound Breast Health Suite with RadNet’s DeepHealth platform, expanding RadNet’s global reach through iCAD’s presence in over 1,500 provider sites across 50+ countries
Ref: Globenewswire | Image: iCAD
Related News:- Siemens to Acquire Dotmatics for $5.1B, Strengthening its Position in Life Science Market
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
